SIRPA and neuroblastoma: Blocking the CD47-SIRPα interaction also increased ADCC capacity in primary patient-derived neuroblastoma spheroid cells as long as GD2 expression was sufficient, once again highlighting the relevance of combination therapy (Figure 4) (171, 172).